FDA gives green light for Regeneron's 12-week Eylea regimen

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) said FDA approved an sBLA for an every 12-week dosing schedule of Eylea aflibercept to treat wet age-related macular degeneration (AMD).

Eylea's updated label says patients may be treated with every 12-week doses after a year of effective therapy "although not as effective as the recommended every 8 week dosing regimen."...